Blueprint Medicines Corporation Surges to 96th in Daily Rankings with $862 Million Turnover

On July 14, 2025, Blueprint Medicines Corporation (BPMC) saw a significant surge in trading volume, with a total turnover of $862 million, marking an 86.84% increase from the previous day. This substantial rise in trading activity placed BPMC at the 96th position in the daily stock market rankings.

Blueprint Medicines Corporation is currently under investigation by Monteverde & Associates PC, a prominent class action law firm based in New York City. The firm is examining the proposed acquisition of Blueprint by Sanofi, S.A., which involves a cash payment of $129.00 per share at closing. Additionally, Blueprint shareholders will receive one non-tradeable contingent value right (CVR) entitling them to potential milestone payments of $2.00 and $4.00 per CVR for the achievement of future development and regulatory milestones for BLU-808.

Monteverde & Associates PC is recognized for its successful track record in recovering millions of dollars for shareholders and is listed as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is encouraging shareholders to contact them for more information and to discuss their legal options regarding the proposed transaction.